Skip to main content

Pender Growth Fund Portfolio Company, General Fusion Inc., Commences Trading

VANCOUVER, British Columbia, July 13, 2026 (GLOBE NEWSWIRE) — (TSXV: PTF): Pender Growth Fund Inc. (the “Company” or “PTF”) is pleased to report that the business combination of long-time holding General Fusion Inc. (“General Fusion”) with Spring Valley Acquisition Corp. III (“SVAC”) (the “Business Combination”), closed on July 10, 2026. On closing, Spring Valley Acquisition Corp. III was renamed “General Fusion Group Ltd”. The combined company’s shares and warrants commenced trading on the Nasdaq on July 13, 2026 under the ticker symbols “GFUZ” and “GFUZW” respectively. General Fusion’s Nasdaq listing comes at an important moment in the evolution of fusion energy. For decades, fusion energy has been regarded as one of science’s greatest engineering challenges. Today however, it is increasingly emerging as a strategic...

Continue reading

Amundi : Programme de rachat d’actions – Déclaration des transactions sur actions propres réalisées du 6 au 10 juillet 2026

Communiqué de Presse Programme de rachat d’actionsDéclaration des transactions sur actions propres réalisées du 06 juillet au 10 juillet 2026 Paris, 13 Juillet 2026 – (Article 5 du règlement (UE) n° 596/2014 sur les abus de marché et Article 3(3) du règlement délégué (UE) 2016/1052 complétant le règlement (UE) n° 596/2014 par des normes techniques de réglementation concernant les conditions applicables aux programmes de rachat et aux mesures de stabilisation).Nom de l’émetteur Code Identifiant de l’émetteur Jour de la transaction Code identifiant de l’instrument financier Volume total journalier (en nombre d’actions) Prix pondéré moyen journalier d’acquisition des actions MarchéAmundi 96950010FL2T1TJKR531 2026-07-06 FR0004125920 13728 89,163334 CCXEAmundi 96950010FL2T1TJKR531 2026-07-06 FR0004125920 25000 89,053456 XPARAmundi 96950010FL2T1TJKR531 2026-07-07 FR0004125920 15000 88,958250 CCXEAmundi 96950010FL2T1TJKR531 2026-07-07 FR0004125920 25000 88,962630 XPARAmundi 96950010FL2T1TJKR531 2026-07-08 FR0004125920 14998 87,062398 CCXEAmundi 96950010FL2T1TJKR531 2026-07-08 FR0004125920 24999 87,059042 XPARAmundi 96950010FL2T1TJKR531 2026-07-09 FR0004125920 15000 87,336970 CCXEAmundi 96950010FL2T1TJKR531 2026-07-09 FR0004125920 24321 87,339928 XPARAmundi 96950010FL2T1TJKR531 2026-07-10 FR0004125920 15000 87,401947 CCXEAmundi 96950010FL2T1TJKR531 2026-07-10 FR0004125920 25001 87,386591 XPAR      TOTAL 198047 87,963924  Les...

Continue reading

General Fusion Becomes First Publicly Listed Fusion Company

Begins trading on Nasdaq under the ticker symbol “GFUZ” VANCOUVER, British Columbia, July 13, 2026 (GLOBE NEWSWIRE) — General Fusion Group Ltd. (“General Fusion” or the “Company”) (NASDAQ: GFUZ), a leader in the global race to commercialize fusion energy, today began trading on the Nasdaq under the ticker symbol “GFUZ,” following the completion of its previously announced business combination with Spring Valley Acquisition Corp. III (“Spring Valley”). General Fusion is entering the public markets with approximately US$150 million in cash, inclusive of net transaction proceeds from the private placement and trust capital, to advance its practical fusion energy technology. This capital is expected to fund General Fusion’s Lawson program through several key technical milestones, which the Company aims to complete in 2028, with the...

Continue reading

Zealand Pharma – Transactions related to share buy-back program (week 28, 2026)

Company announcement No. 32 / 2026 Zealand Pharma – Transactions related to share buy-back program (week 28, 2026) Copenhagen, Denmark, July 13, 2026 – Zealand Pharma A/S (“the Company” or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 28 (July 6 – July 10, 2026). The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe Harbour Regulation”). Reference is made to company announcement no. 15 / 2026 dated May 7, 2026, which sets out the full terms of the Program. Under the Program, Zealand Pharma may repurchase shares for a total...

Continue reading

Zelluna doses first solid tumour patient with ZI-MA4-1 in the ZIMA-101 Phase 1 trial

First patient dosed with ZI-MA4-1 in the ZIMA-101 Phase 1 trial at The Christie NHS Foundation Trust ZI-MA4-1 is the world’s first MAGE-A4-targeting TCR-NK therapy in clinical development ZIMA-101 represents the first clinical evaluation of Zelluna’s proprietary TCR-NK platform Patient identification, pre-screening and screening activities continue across all four tumour indications included in the study Company on track for initial clinical data to emerge from mid-2026July 13 2026 – Zelluna ASA (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced that the first patient has been given the first dose in ZIMA-101, the Company’s first-in-human Phase 1 clinical trial evaluating ZI-MA4-1, Zelluna’s lead TCR-NK...

Continue reading

Old National Bank Foundation celebrates 20 years, $40+ million in Community Impact

‘20 for 20’ campaign will provide $20,000 to nonprofits across Old National’s footprint EVANSVILLE, Ind., July 13, 2026 (GLOBE NEWSWIRE) — (NASDAQ: ONB) – In celebration of its 20th anniversary and two decades of helping build stronger, more vibrant and prosperous communities, the Old National Bank Foundation is donating a total of $20,000 to 20 nonprofit organizations throughout its nine-state footprint. Since its start in 2006, the Old National Bank Foundation has granted more than $40 million to nonprofit organizations in the communities Old National serves. The most recent grant cycle, with more than 200 grants awarded totaling more than $3 million, was the largest in the Foundation’s history. “For 20 years, the (Old National Bank) Foundation has helped turn compassion into action and possibility into progress for communities...

Continue reading

Genco Shipping & Trading Limited Comments on Extension of $24.80 Per Share Tender Offer by Diana Shipping

Diana Still Has Not Updated Its Tender Offer Materials to Align Terms with Indicative, Non-Binding Proposal NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) — Genco Shipping & Trading Limited (NYSE:GNK) (“Genco” or the “Company”), the largest U.S. headquartered drybulk shipowner focused on the global transportation of commodities, today issued the following statement regarding the extension by Diana Shipping Inc. (“Diana”) of its inadequate tender offer to acquire all outstanding common shares of Genco not already owned by Diana for $24.80 per share in cash: Diana has once again extended its inadequate tender offer for $24.80 per share in cash. Our Board of Directors previously reviewed and unanimously rejected this offer, determining that it continued to meaningfully undervalue the Company and its assets, remained well below Genco’s...

Continue reading

Schouw & Co. share buy-back programme, week 28 2026

On 2 January 2026, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 59 of 18 December 2025. Under the programme, Schouw & Co. will acquire shares for up to DKK 240 million during the period 2 January to 31 December 2026. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules).Trading day No. of shares Average price Amount DKK    Accumulated until 3 July 2026 177,283 655.64 116,234,473    Monday, 6 July 2026 4,000 604.00 2,416,000    Tuesday, 7 July 2026 4,000 606.85 2,427,406    Wednesday, 8 July 2026 4,000 613.46 2,453,844    Thursday, 9 July 2026 4,000 619.78 2,479,108    Friday,...

Continue reading

Davidson Kempner Capital Management LP : Form 8.3 – easyJet Plc

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: Davidson Kempner Capital Management LP(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree easyJet plc(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)   Date position held/dealing undertaken:        For...

Continue reading

Form 8 (Opening Position Disclosure) – System1 Group plc – Octopus Investments

FORM 8 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)        Full name of discloser: OCTOPUS INVESTMENTS LTD(b)        Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree System1 Group plc(d)        If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)        Date position held/dealing undertaken:...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.